Tempus AI Q2 FY26 swings to GAAP profit of $5.64 million; revenue rises 22% to $382.5 million
TEM•Q2 revenue, profit and EBITDA improve
Tempus AI posted Q2 revenue of $382.5 million, up 22% year-over-year; GAAP net income swung to $5.6 million.
Adjusted EBITDA turned positive at $8 million; oncology volume rose 31% year-over-year, while MRD volume climbed to 9,000 tests from 6,500 last quarter.
Data business growth, licensing wins and guidance increase
Data and Applications revenue increased 28% year-over-year to $93.2 million; Data Licensing & Modeling (Insights) revenue rose 36%.
The company signed about $200 million in new Data and Applications licenses; the FDA cleared the tumor-only xT CDx assay, enabling migration of tissue testing to ADLT pricing.
Tempus AI raised 2026 revenue guidance to $1.595 billion-$1.605 billion and reiterated expected full-year adjusted EBITDA of about $65 million.
